Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02359019 · ClinicalTrials.gov registry record · Phase 2
MK-3475 as Maintenance Therapy in Extensive Stage SCLC
A Phase 2 study of Extensive Stage Small Cell Lung Carcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 5
- Study locations
NCT02359019: Completed Phase 2 study of Extensive Stage Small Cell Lung Carcinoma, sponsored by Barbara Ann Karmanos Cancer Institute.
NCT02359019 is a Phase 2 study of Extensive Stage Small Cell Lung Carcinoma that has completed, run by Barbara Ann Karmanos Cancer Institute. The registered enrollment target is 45 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02359019, a Phase 2 study of Extensive Stage Small Cell Lung Carcinoma, has completed, sponsored by Barbara Ann Karmanos Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stable disease after completion of combination chemotherapy.
Primary Outcome
Progression is defined using RECIST 1.1. PFS will be estimated with the standard Kaplan-Meier method, from which summary statistics of interest (median, 1-year rate, etc.) will be derived. Both point and 95% confidence interval estimates of PFS will be calculated.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- OTHER Laboratory Biomarker Analysis
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Barbara Ann Karmanos Cancer Institute - Detroit
Illinois
- Rush University Medical Center - Chicago
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- Penn State Milton S. Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-02 |
| Est. Completion | 2018-10 |
| Phase | Phase 2 |
What the finished NCT02359019 record still lists
NCT02359019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Extensive Stage Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT02359019 lists 5 locations in 4 states (Michigan, Illinois, Ohio).
Frequently Asked Questions
What is clinical trial NCT02359019 about?
NCT02359019 is a clinical study titled "MK-3475 as Maintenance Therapy in Extensive Stage SCLC". This phase II trial studies how well pembrolizumab works in treating patients with extensive stage small cell lung cancer after completion of combination chemotherapy. Pembrolizumab may be effective in controlling small cell lung cancer for a longer period of time in patients with responsive or stab...
What is the current status of trial NCT02359019?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-02. Estimated completion is 2018-10.
What conditions does trial NCT02359019 study?
This clinical trial studies the following conditions: Extensive Stage Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT02359019?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT02359019?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02359019 being conducted?
This trial has 5 study locations across Illinois, Michigan, Ohio, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive Stage Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02359019's enrollment target sits among peer trials
45 1296th of 2000 higher than 679 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia